News

Henrik Watz Featured in Free Educational Presentation Available for HCPs on COPD with Type 2 Inflammation

Congratulations to Henrik Watz, MD, on his exceptional presentation at the 2024 European Respiratory Society (ERS) ADVENT COPD Symposia! Dr. Watz, Medical Director and Principal Investigator at Velocity Clinical Research in Ahrensburg, Germany, joined Drs. Mona Bafadhel and Alberto Papi for a dynamic discussion, A Breath of Fresh Air: A Greater Understanding of COPD With … Read more

Velocity Targets Latin America Expansion with the Appointment of Renata Berardocco as LATAM Managing Director

Velocity Clinical Research, the leading fully integrated clinical site organization, announces the appointment of Renata Berardocco as Executive Vice President and Managing Director for the Latin America (LATAM) region. Renata has nearly two decades of experience in senior leadership roles and joins from Fortrea, where she led Clinical Operations Delivery and Clinical Projects.  LATAM represents … Read more

Respiratory Health Priorities are Changing Across Europe – What Role Do Clinical Trial Sites Have to Play?

For decades, research into respiratory health has centered on conditions such as asthma and chronic obstructive pulmonary disease (COPD), predominantly because of their high prevalence. However, the incidence of respiratory diseases is increasing globally, with lesser-researched but equally debilitating conditions such as interstitial lung disease, pulmonary sarcoidosis, and pneumoconiosis affecting health statuses worldwide.  While clinical … Read more

Kris Kowdley, MD, Presents Positive Late-Breaking Data for Ipsen’s Iqirvo® at AASLD

Kris Kowdley, MD, AGAF, FAASLD, FACP, FACG, presented late-breaking data for Iqirvo® (elafibranor), Ipsen’s treatment for primary biliary cholangitis (PBC), at American Association for the Study of Liver Diseases (AASLD). “Over three years, Iqirvo data suggest sustained efficacy and support the safety profile of the medicine,” said Dr. Kowdley. “Importantly, when patients tell me they … Read more

The Start of Germany’s National Pharma Strategy: Implications for CROs and Clinical Trials

Over the past decade, Germany’s share of global clinical trial activities has dropped year on year. The country accounted for just 3.9% of trials in 2021, down from 7.2% in 2012. Late last year, the German Government published its National Pharma Strategy, which is designed to reverse this trend. Aiming to revitalize the country’s pharmaceutical … Read more

Velocity Enrolled 8,000+ Participants in Trials in October

Velocity enrolled more than 8,000 participants in clinical trials in October, marking our highest-ever enrollment in a single month. This required many long hours and thoughtful solutioning from so many across the organization. A special thank you to our site staff and Recruitment team, who continuously rise to every challenge and keep patient care and … Read more

Velocity Named Among the Top 50 Operations Teams at the 2024 OnCon Icon Awards

Velocity has been recognized among the Top 50 Operations Teams at the 2024 OnCon Icon Awards! This award is especially meaningful because it’s based on peer and community votes, reflecting the operational excellence our team continues to build as we scale globally. Thank you to OnConferences, to everyone who voted, and to our exceptional team … Read more

Scaling With a Purpose: Championing the Clinical Trials Sector

At the beginning of September, Velocity Clinical Research topped Business North Carolina’s 2024 Fast 40 list. It was our third time receiving the award, which recognizes the fastest-growing mid-market businesses in the state. For a clinical trials organization to achieve this level of scale is notable. The clinical trials sector in the US is typically … Read more